Bayer, Versant join forces on $225M Series A for stem cell upstart – FierceBiotech
FierceBiotech |
Bayer, Versant join forces on $225M Series A for stem cell upstart
FierceBiotech The startup, which is being hailed by the pair as a “next-generation regenerative medicine company” plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies. Its initial focus will be on CNS and CV disease areas, the companies said … Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 … Bayer launches stem cell therapy company BlueRock Therapeutics Bayer, Versant invest $225 million in biotech venture |
